Journal of Preventive Medicine and Public Health

The Korean Society for Preventive Medicine (대한예방의학회)
권호 표지
DOI QR코드

DOI QR Code

Vaccination Status and In-hospital Mortality Among Adults With COVID-19 in Jakarta, Indonesia: A Retrospective Hospital-based Cohort Study

  • Received : 2023.08.16
  • Accepted : 2023.10.20
  • Published : 2023.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives: Prospective studies on vaccination status and mortality related to coronavirus disease 2019 (COVID-19) in low-resource settings are still limited. We assessed the association between vaccination status (full, partial, or none) and in-hospital mortality among COVID-19 patients at most hospitals in Jakarta, Indonesia during the Delta predomination wave. Methods: We conducted a retrospective cohort study among hospitalized COVID-19 patients who met the study criteria (>18 years old and admitted for inpatient treatment because of laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection). We linked individual-level data in the hospital admission database with vaccination records. Several socio-demographic and clinical characteristics were also analyzed. A Cox proportional hazards regression model was used to explore the association between vaccination status and in-hospital mortality in this patient group. Results: In total, 40 827 patients were included in this study. Of these, 70% were unvaccinated (n=28 543) and 19.3% (n=7882) died during hospitalization. The mean age of the patients was 49 years (range, 35-59), 53.2% were female, 22.0% had hypertension, and 14.2% were treated in the intensive care unit, and the median hospital length of stay across the group was 9 days. Our study showed that the risk of in-hospital mortality among fully and partially vaccinated patients was lower than among unvaccinated adults (adjusted hazard ratio [aHR], 0.43; 95% confidence interval [CI], 0.40 to 0.47 and aHR, 0.70; 95% CI, 0.64 to 0.77, respectively). Conclusions: Vaccinated patients had fewer severe outcomes among hospitalized adults during the Delta wave in Jakarta. These features should be carefully considered by healthcare professionals in treating adults within this patient group.

Keywords

Acknowledgement

We would like to thank Dr Anas Ma'ruf, Haidar Istiqlal, Maria Ulfa Amidya at the Ministry of Health Indonesia; Made Darmawan and Akbar Antony Siregar at the National COVID-19 Control and Economic Recovery Committee (KPC-PEN) for their assistance and support in providing the hospitalization and vaccination data.

References

  1. World Health Organization. WHO coronavirus (COVID-19) dashboard [cited 2023 Mar 11]. Available from: https://covid19.who.int/.
  2. Ministry of Health of Indonesia. COVID-19 dashboard [cited 2023 Mar 15]. Available from: https://infeksiemerging.kemkes.go.id/dashboard/covid-19 (Indonesian).
  3. Gunadi, Hakim MS, Wibawa H, Marcellus, Setiawaty V, Slamet, et al. Is the infection of the SARS-CoV-2 Delta variant associated with the outcomes of COVID-19 patients? Front Med (Lausanne) 2021;8:780611.
  4. Haileamlak A. The impact of COVID-19 on health and health systems. Ethiop J Health Sci 2021;31(6):1073-1074.
  5. Sparke M, Levy O. Competing responses to global inequalities in access to COVID vaccines: vaccine diplomacy and vaccine charity versus vaccine liberty. Clin Infect Dis 2022;75(Suppl 1):S86-S92. https://doi.org/10.1093/cid/ciac361
  6. Choi EM. COVID-19 vaccines for low- and middle-income countries. Trans R Soc Trop Med Hyg 2021;115(5):447-456. https://doi.org/10.1093/trstmh/trab045
  7. Ma C, Sun W, Tang T, Jia M, Liu Y, Wan Y, et al. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: evidence from an outbreak in Yunnan, China, 2021. Vaccine 2022;40(20):2869-2874. https://doi.org/10.1016/j.vaccine.2022.03.067
  8. Huespe IA, Ferraris A, Lalueza A, Valdez PR, Peroni ML, Cayetti LA, et al. COVID-19 vaccines reduce mortality in hospitalized patients with oxygen requirements: differences between vaccine subtypes. A multicontinental cohort study. J Med Virol 2023;95(5):e28786.
  9. Lee SW, Ma D, Davoodian A, Ayutyanont N, Werner B. COVID-19 vaccination decreased COVID-19 hospital length of stay, in-hospital death, and increased home discharge. Prev Med Rep 2023;32:102152.
  10. Muthukrishnan J, Vardhan V, Mangalesh S, Koley M, Shankar S, Yadav AK, et al. Vaccination status and COVID-19 related mortality: a hospital based cross sectional study. Med J Armed Forces India 2021;77:S278-S282. https://doi.org/10.1016/j.mjafi.2021.06.034
  11. Li M, Lou F, Fan H. SARS-CoV-2 variants of concern Delta: a great challenge to prevention and control of COVID-19. Sig Transduct Target Ther 2021;6:349.
  12. Ministry of Health of the Republic of Indonesia, Ministry of Communication and Information Technology of the Republic of Indonesia. Joint Decree on one COVID-19 vaccination data. Jakarta: Ministry of Health of the Republic of Indonesia; 2021, p.13 (indonesian).
  13. Ministry of Health of the Republic of Indonesia. Latest news on coronavirus disease (COVID-19), 23 November 2021 [cited 2023 Mar 11]. Available from: https://infeksiemerging.kemkes.go.id/index.php/situasi-infeksi-emerging/situasi-terkini-perkembangan-coronavirus-disease-covid-19-23-november-2021 (Indonesian).
  14. Rosenthal N, Cao Z, Gundrum J, Sianis J, Safo S. Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19. JAMA Netw Open 2020;3(12):e2029058.
  15. Taylor CA, Whitaker M, Anglin O, Milucky J, Patel K, Pham H, et al. COVID-19-associated hospitalizations among adults during SARS-CoV-2 Delta and Omicron variant predominance, by race/ethnicity and vaccination status - COVID-NET, 14 states, July 2021-January 2022. MMWR Morb Mortal Wkly Rep 2022;71(12):466-473. https://doi.org/10.15585/mmwr.mm7112e2
  16. Liang XM, Xu QY, Jia ZJ, Wu MJ, Liu YY, Lin LR, et al. A third dose of an inactivated vaccine dramatically increased the levels and decay times of anti-SARS-CoV-2 antibodies, but disappointingly declined again: a prospective, longitudinal, cohort study at 18 serial time points over 368 days. Front Immunol 2022;13:876037.
  17. World Health Organization. The Sinovac-CoronaVac COVID-19 vaccine: what you need to know; 2022 Jun 10 [cited 2023 Mar 15]. Available from: https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know?gclid=Cj0KCQiAo7KqBhDhARIsAKhZ4uhvjYOWxJQUlunY-byP9F_TzCaBTsm9vzWb_NdLuC-IZidzPXoFK_caAmEFEALw_wcB.
  18. Social Health Insurance Administration Body. How to use Pcare [cited 2023 Mar 15]. Available from: https://indonesia.go.id/kategori/kesehatan/1139/cara-gunakan-pcare-bpjs-kesehatan?lang=1 (Indonesian).
  19. Centers for Disease Control and Prevention. National center for health statistics International Classification of Diseases, (ICD-10-CM/PCS) transition - background; 2021 [cited 2023 Mar 15]. Available from: https://www.cdc.gov/nchs/icd/icd10.htm.
  20. Mishra P, Pandey CM, Singh U, Gupta A, Sahu C, Keshri A. Descriptive statistics and normality tests for statistical data. Ann Card Anaesth 2019;22(1):67-72. https://doi.org/10.4103/aca.ACA_157_18
  21. Lee SW. Regression analysis for continuous independent variables in medical research: statistical standard and guideline of Life Cycle Committee. Life Cycle 2022;2:e3.
  22. Grant SW, Hickey GL, Head SJ. Statistical primer: multivariable regression considerations and pitfalls. Eur J Cardiothorac Surg 2019;55(2):179-185. https://doi.org/10.1093/ejcts/ezy403
  23. Gopalan N, Senthil S, Prabakar NL, Senguttuvan T, Bhaskar A, Jagannathan M, et al. Predictors of mortality among hospitalized COVID-19 patients and risk score formulation for prioritizing tertiary care-an experience from South India. PLoS One 2022;17(2):e0263471.
  24. Calabuig JM, Garcia-Raffi LM, Garcia-Valiente A, Sanchez-Perez EA. Kaplan-Meier type survival curves for COVID-19: a health data based decision-making tool. Front Public Health 2021;9:646863.
  25. Rahman MS, Harun MG, Sumon SA, Mohona TM, Abdullah SA, Khan MN, et al. Hospitalization and mortality by vaccination status among COVID-19 patients aged ≥25 years in Bangladesh: results from a multicenter cross-sectional study. Vaccines (Basel) 2022;10(12):1987.
  26. Grapsa E, Adamos G, Andrianopoulos I, Tsolaki V, Giannakoulis VG, Karavidas N, et al. Association between vaccination status and mortality among intubated patients with COVID-19-related acute respiratory distress syndrome. JAMA Netw Open 2022;5(10):e2235219.
  27. Derrough T, Olsson K, Gianfredi V, Simondon F, Heijbel H, Danielsson N, et al. Immunisation Information Systems - useful tools for monitoring vaccination programmes in EU/EEA countries, 2016. Euro Surveill 2017;22(17):30519.
  28. Huang YZ, Kuan CC. Vaccination to reduce severe COVID-19 and mortality in COVID-19 patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2022;26(5):1770-1776.
  29. Shekhar R, Garg I, Pal S, Kottewar S, Sheikh AB. COVID-19 vaccine booster: to boost or not to boost. Infect Dis Rep 2021;13(4):924-929. https://doi.org/10.3390/idr13040084
  30. Suthar AB, Wang J, Seffren V, Wiegand RE, Griffing S, Zell E. Public health impact of covid-19 vaccines in the US: observational study. BMJ 2022;377:e069317.
  31. European Centre for Disease Prevention and Control. Risk of SARS-CoV-2 transmission from newly-infected individuals with documented previous infection or vaccination; 2021 Mar 29 [cited 2023 Aug 1]. Available from: https://www.ecdc.europa.eu/en/publications-data/sars-cov-2-transmission-newly-infected-individuals-previous-infection#no-link.
  32. Prunas O, Warren JL, Crawford FW, Gazit S, Patalon T, Weinberger DM, et al. Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel. Science 2022;375(6585):1151-1154. https://doi.org/10.1126/science.abl4292
  33. Sheikh A, McMenamin J, Taylor B, Robertson C; Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 2021;397(10293):2461-2462. https://doi.org/10.1016/S0140-6736(21)01358-1
  34. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ 2020;11(1):29.
  35. Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun 2020;11(1):6317.
  36. Thorsteinsdottir B, Madsen BE. Prioritizing health care workers and first responders for access to the COVID19 vaccine is not unethical, but both fair and effective - an ethical analysis. Scand J Trauma Resusc Emerg Med 2021;29(1):77.
  37. Thakur B, Dubey P, Benitez J, Torres JP, Reddy S, Shokar N, et al. A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep 2021;11(1):8562.
  38. Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Aghayari Sheikh Neshin S, Khatami A, et al. Effectiveness of COVID-19 vaccines against Delta (B.1.617.2) variant: a systematic review and meta-analysis of clinical studies. Vaccines (Basel) 2021;10(1):23.